Newnorm — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-09 (month) in 26d
ESTIMATED |
READOUT
Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Su
Phase 3 · Primary Immune Deficiency |
Octapharma | Newnorm |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|